急性髓系白血病患者骨髓细胞相关分子标志物表达研究  

Expression of Biomarkers Related with Bone Marrow Cells in Patients with Acute Myelogenous Leukemia

作　　者：黄晓[1] 王荣华[1,2] 李冬云[1] 赖宗浪[1] 褚雨霆[1] 张宇[1] 陈信义[1,3] 

机构地区：[1]北京中医药大学东直门医院肿瘤血液科,北京100700 [2]美国耶鲁大学医学院流行病与公共卫生系,美国康涅狄格州纽黑文06520 [3]北京市、教育部重点实验室(中医内科学),北京100700

出　　处：《中国实验血液学杂志》2014年第5期1193-1198,共6页Journal of Experimental Hematology

基　　金：高等学校博士点科研专项(20100013110008);北京市支持中央在京高校共建项目

摘　　要：本研究旨在探讨急性髓系白血病患者骨髓细胞相关分子标志物(PTEN、mTOR、NF-kB、CD44、PI3K)表达。选取20例住院患者,抽取骨髓液,先涂片检查骨髓白血病细胞百分比,并分临床缓解(9例)与未缓解(11例)两组。再将剩余的骨髓液以石蜡包埋,常规切片,免疫组化技术检测PTEN、mTOR、NF-kB、CD44、PI3K表达。结果表明:光学显微镜观察缓解组与未缓解组PTEN、mTOR、NF-kB、CD44、PI3K阳性细胞表达率分别为33.3、33.3、77.8、22.2、0与63.6,18.2,90.9,63.6,0。经统计学处理,PTEN和CD44两组比较,有统计学意义(P<0.05),荧光表达强度与图像分析也得出同样的研究结果。结论表明:急性白血病骨髓细胞PTEN、CD44高表达可作为急性髓系白血病难治诊断和预后判定的重要参考指标。This study was aimed to investigate the expression of biomarkers（PTEN,mTOR,NF-kB,CD44,PI3K） related with bone marrow cells in patients with acute myelogenous leukemia.The immunohistochemical method was used to detect the expression of PTEN,mTOR,NF-kB,CD44,PI3K in 20 patients.The AML patients were divided into remission group and non-remission group after calculating the percentage of leukemia cells in bone marrow.The results showed that by optical microscopy,the positive expression rates of PTEN,mTOR,NF-kB,CD44 and PI3K in remission group were 33.3%,33.3%,77.8%,22.2%,0,respectively; meanwhile,in non-remission group,the positive expression rates of above-menthioned biomarkers were 63.6%,18.2,90.9,63.6%,0,respectively.The percentage and mean OD for PTEN and CD44 were statistically different between the two groups （P 〈 0.05）,but for mTOR,NF-kB and PI3 K were not statstically differenly （P 〉 0.05）.It is concluded that the high expression of PTEN and CD44 can be regarded as an important index for diagnosis and prognosis in acute myelogenous leukemia.

关 键 词：急性髓系白血病 骨髓细胞 分子标志物 PTEN CD44 

分 类 号：R733.71[医药卫生—肿瘤]